272 related articles for article (PubMed ID: 27101098)
21. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
22. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
23. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract][Full Text] [Related]
24. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
26. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
28. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.
Chuang YT; Chang CL
Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913
[TBL] [Abstract][Full Text] [Related]
29. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247
[TBL] [Abstract][Full Text] [Related]
30. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
32. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
33. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
38. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
39. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]